On Friday, Shares of Marketo, Inc. (NASDAQ:MKTO), gained 4.39% to $29.70.
Marketo, declared its first quarter 2015 financial results.
Highlights:
- First quarter revenue raised 42 percent year over year to $46.0 million
- Deferred revenue raised 47 percent year over year to $66.9 million
- First quarter calculated billings raised 37 percent year over year to $49.9 million
- Subscription dollar retention rate was 109 percent
- Customer count raised to 3,972.
Marketo, Inc. provides cloud-based marketing software platform that enables organizations to engage in relationship marketing in the United States. The company’s Engagement Marketing Platform enables the execution, administration, and analytical measurement of online, social, and offline marketing activities and customer interactions.
At the end of Friday’s trade, Shares of Dyax Corp. (NASDAQ:DYAX), jumped 4.37% to $24.95.
Dyax Corp., declared financial results for the first quarter ended March 31, 2015. Dyax will host a webcast and conference call at 5:00 p.m. (ET) recently to review financial results and provide updates regarding its key value drivers – counting DX-2930, KALBITOR® (ecallantide), and the Licensing and Funded Research Portfolio (LFRP).
Recent highlights comprise:
- Stated positive safety, pharmacokinetic, biomarker and proof-of-concept efficacy results from the Phase 1b study of DX-2930 in hereditary angioedema (HAE) patients;
- Receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for the investigation of DX-2930 for HAE;
- KALBITOR net sales were $16.0 million for the first quarter of 2015;
- Dyax’s licensee Eli Lilly and Company received FDA approval for CYRAMZA® (ramucirumab), in a fourth indication, for use with FOLFIRI (irinotecan, folinic acid and 5-fluorouracil) in the second-line treatment of metastatic colorectal cancer; and
- Cash, cash equivalents and investments at March 31, 2015 totaled $181.9 million, not taking into account net proceeds of $215.8 million from the April 2015 public offering of common stock.
Dyax Corp., a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and other plasma-kallikrein-mediated (PKM) disorders. It offers KALBITOR for the treatment of acute attacks of HAE.
Finally, Ultra Petroleum Corp. (NYSE:UPL), closed at $17.77, with 4.35% gain.
Ultra Petroleum, stated first quarter 2015 operating and financial results. Highlights comprise:
- Produced natural gas and oil volumes of 70.4 Bcfe, an enhance of 23% above year ago levels
- Generated operating cash flow of $111.4 million
- Generated earnings of $21.1 million or $0.14 per diluted share – adjusted
- 45 percent cash flow margin.
Ultra Petroleum stated adjusted net income of $21.1 million, or $0.14 per diluted share for the first quarter of 2015. Operating cash flow, was $111.4 million for the quarter ended March 31, 2015.
For the first quarter of 2015, production of natural gas and oil was 70.4 billion cubic feet equivalent (Bcfe). The company’s production for the first quarter was comprised of 64.7 billion cubic feet (Bcf) of natural gas and 951.1 thousand barrels (Mbbls) of oil and condensate.
During the first quarter of the year, Ultra Petroleum’s average realized natural gas price was $3.29 per thousand cubic feet (Mcf), counting realized gains and losses on commodity hedges. Not taking into account realized gains and losses on commodity derivatives, the company’s average price for natural gas was $2.84 per Mcf. The company’s average realized oil and condensate price was $37.34 per barrel (Bbl).
First quarter 2015 results comprised of an unrealized, mark-to-market gain of $7.5 million on the company’s commodity hedges. The unrealized gain is typically excluded by the investment community in published estimates.
Ultra Petroleum Corp., an independent oil and gas company, engages in the acquisition, exploration, development, production, and operation of oil and natural gas properties in the United States. It primarily focuses on developing natural gas reserves in the Green River Basin of Wyoming; oil reserves in the Uinta Basin of Utah; and natural gas reserves in the Appalachian Basin of Pennsylvania.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
